ArticleNPJ precision oncology2022

Disease progression patterns and molecular resistance mechanisms to crizotinib of lung adenocarcinoma harboring ROS1 rearrangements.

Yongchang Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.